Durvalumab Pre, Post Surgery in NSCLC: Practice Changing? ...Middle East

The AEGEAN trial is the second phase 3 study, after Checkmate 816, to demonstrate a benefit from neoadjuvant immunotherapy for patients with resectable non–small cell lung cancer. Medscape Medical News

Hence then, the article about durvalumab pre post surgery in nsclc practice changing was published today ( Thursday 20/04/2023 - 06:08 PM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Durvalumab Pre, Post Surgery in NSCLC: Practice Changing? )

Also on site :

• Nokia Strengthens Edge AI Capabilities Through Strategic Collaboration with Blaize on Hybrid Inference Solutions Across Asia Pacific Regions
• 7 ‘Old-School’ Parenting Phrases Boomers Still Use That Can Come Across as Dismissive
• This New Alaska Cruise Excursion Lets You Get Surprisingly Close to Moose